June MIMS update

We look at some of the recent changes to the medicines landscape, with new products, new indications and safety related changes  New Products Deucravacitinib (Sotyktu) is a small molecule that selectively inhibits the tyrosine kinase 2 (TYK2) enzyme. It binds to the regulatory domain of TYK2, stabilising an inhibitory interaction between the regulatory and the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous It’s a “Transition of Care Stewardship” kind of morning...
Next Kidney damage warning